Characterizing predictive parameters of GATA2 gene mutation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to characterize predictive parameters of clonal evolution in patients with a germline GATA2 mutation. It involves a multi-site, open-label cohort of 250 patients, including both previously identified and newly diagnosed individuals with the mutation. Biological samples, including blood and bone marrow, will be collected from participants over a five-year period to analyze the mutation's effects. The study will help understand the progression and implications of the GATA2 mutation in affected individuals.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. All subject, at any age, with a germline GATA2 mutation.
2. Patient followed in the center within a standard of care procedure or clinical trial.
3. Signed written informed consent. For minor patients: patient assent and legal guardian(s) written informed consent obtained before inclusion in the study and prior performance of any study-related procedure.
4. For French patients: patient affiliated to a Social Health Insurance.

Exclusion Criteria:

1. GATA2 somatic mutation.
2. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure.
3. Person who has forfeited his/her freedom by administrative or legal award or who is under legal protection, with the exception of persons under curatorship who may be included in the study.

Where it's running

• CHU Angers
  Angers, France Recruiting
• CHU Bordeaux
  Bordeaux, France Recruiting
• CHU Estaing
  Clermont-Ferrand, France Recruiting
• CHU Dijon
  Dijon, France Recruiting
• CHU de Grenoble
  Grenoble, France Recruiting
• CHRU - Lille
  Lille, France Recruiting

Study contacts

• Study coordinator: Marlène PASQUET
• Email: pasquet.m@chu-toulouse.fr
• Phone: +33 5 34 55 86 08

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Routine shallow-coverage Whole Genome Sequencing of Cervical Smears to See if Ovarian Cancer is Found Earlier

  Researchers test whether analyzing DNA from cervical smears with shallow whole-genome sequencing can help detect high-grade serous ovarian cancer early in patients undergoing treatment for this cancer.

  Recruiting Institut Claudius Regaud · Toulouse · NCT07821879

• Male Breast Cancer Predisposition Factor: Create a Control Group

  This study tests genetic and psychosocial data in men who are relatives of men with breast cancer but who themselves have no cancer history.

  Recruiting Institut Claudius Regaud · Toulouse · NCT07558343

• Biomarkers and immune responses in early-stage solid cancers treated with immunotherapy

  This study tests immune biomarkers in patients with early-stage solid cancers who are receiving immune checkpoint blockade before surgery.

  Recruiting Institut Claudius Regaud · Toulouse and 2 other locations · NCT07427186

• Atlas of cell organelles and protein patterns in breast cancer subtypes

  This project will collect tumor and blood samples from people with early or newly metastatic breast cancer to test how much fat accumulates in tiny cell structures (lipid droplets) and to map protein patterns across tumor subtypes.

  Recruiting Institut Claudius Regaud · Toulouse · NCT07233928

• Comparing blood levels of the free‑DXd payload from trastuzumab‑deruxtecan by BMI in people with advanced or metastatic breast cancer

  This study will test whether body mass index changes blood levels of the free‑DXd payload in adults with locally advanced or metastatic HER2‑low or HER2‑positive breast cancer who are receiving trastuzumab‑deruxtecan.

  Recruiting at 6 sites Phase 4 Institut Claudius Regaud · Angers and 9 other locations · NCT07195344

• Detecting double-positive (tumor marker/CD45+) cells in the blood of people with metastatic cancer

  This one-day study will test two blood-based methods to find double-positive tumor/CD45+ circulating cells in adults who are about to start treatment for various metastatic cancers.

  Recruiting Institut Claudius Regaud · Toulouse · NCT06967961

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.